Costs and Factors Associated with Hospitalizations Due to Severe Influenza in Catalonia (2017–2020)

Mercè Soler-Font, Ignacio Aznar-Lou (), Luca Basile, Núria Soldevila, Pere Godoy, Ana Martínez, Antoni Serrano-Blanco, Angela Domínguez and The Surveillance of Hospitalized Cases of Severe Influenza in Catalonia Working Group
Additional contact information
Mercè Soler-Font: PRISMA Research Group, Institut de Recerca Sant Joan de Déu, Santa Rosa 39-57, 08950 Esplugues de Llobregat, Spain
Ignacio Aznar-Lou: PRISMA Research Group, Institut de Recerca Sant Joan de Déu, Santa Rosa 39-57, 08950 Esplugues de Llobregat, Spain
Luca Basile: Public Health Agency of Catalonia, Department of Health, Roc Boronat, 81-95, 08005 Barcelona, Spain
Núria Soldevila: Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Monforte de Lemos 3-5, 28029 Madrid, Spain
Pere Godoy: Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Monforte de Lemos 3-5, 28029 Madrid, Spain
Ana Martínez: Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Monforte de Lemos 3-5, 28029 Madrid, Spain
Antoni Serrano-Blanco: PRISMA Research Group, Institut de Recerca Sant Joan de Déu, Santa Rosa 39-57, 08950 Esplugues de Llobregat, Spain
Angela Domínguez: Consortium for Biomedical Research in Epidemiology & Public Health (CIBERESP), Monforte de Lemos 3-5, 28029 Madrid, Spain
The Surveillance of Hospitalized Cases of Severe Influenza in Catalonia Working Group: The Surveillance of Hospitalized Cases of Severe Influenza in Catalonia Working Group: Alsedà M., Álvarez J., Arias C., Balañà P.J., Camps N., Carol M., Curto L., Ferràs J., Ferrús G., Follia N., Bach P., Minguell S., Parrón I., Plasència E., Sala-Farré M.R., Torra R., Torres J. (Public Health Agency of Catalonia); Barrabeig I., Godoy P., Jané M., Martínez A., Torner N. (Public Health Agency of Catalonia and CIBERESP); Garcia M., Gorrindo P. (Public Health Agency of Barcelona), Rius C. (Public Health Agency of Barcelona and CIBERESP); Marcos M.A., Mosquera M.M., Vila J., Vilella A. (H Clínic, Barcelona); Antón A., Pumarola T., Campins M. (H Universitari Vall d’Hebrón, Barcelona); García D., Oller Perez-Hita A. (H Josep Trueta, Girona); Andres M., Espejo E. (H Terrassa); Freixas N., Lopez M., Porta C., Riera Garcia M. (Mútua Terrassa); Maraver E., Mas D., Pérez R., (H Altahia Manresa); Rebull J. (H.Verge de la Cinta, Tortosa); Muñoz S., Pou J. (H Sant Joan de Déu, Esplugues); García-Pardo G., Olona M. (H Joan XXIII, Tarragona); Barcenilla F., Castellana D. (H Arnau de Vilanova, Lleida); Navarro-Rubio G. (Consorci Sanitari Parc Taulí, Sabadell); Force L.L. (H Mataró); Mena G., Mòdol-Deltell J.M. (H Germans Trias i Pujol); Alvarez A., Massuet C., Ramon J.M. (H U Bellvitge); Lopez A.F., Iftimie S.M., Garrido P. (HU Sant Joan de Reus); Blancas D., Moreno E. (Hospital Residència Sant Camil).

IJERPH, 2022, vol. 19, issue 22, 1-10

Abstract: This study aimed to estimate the cost and factors associated with severe hospitalized patients due to influenza in unvaccinated and vaccinated cases. The study had a cross-sectional design and included three influenza seasons in 16 sentinel hospitals in Catalonia, Spain. Data were collected from a surveillance system of influenza and other acute respiratory infections. Generalized linear models (GLM) were used to analyze mean costs stratified by comorbidities and pregnancy. Multivariate logistic models were used to analyze bacterial coinfection, multi-organ failure, acute respiratory distress syndrome, death and ICU admission by season and by vaccination status. Costs of ICU, hospitalization and total mean costs were analyzed using GLM, by season and by vaccination status. All models were adjusted for age and sex. A total of 2742 hospitalized cases were included in the analyses. Cases were mostly aged ≥ 60 years (70.17%), with recommended vaccination (86.14%) and unvaccinated (68.05%). The ICU admission level was statistically significant higher in unvaccinated compared to vaccinated cases. Costs of cases with more than or equal to two comorbidities (Diff = EUR − 1881.32), diabetes (Diff = EUR − 1953.21), chronic kidney disease (Diff = EUR − 2260.88), chronic cardiovascular disease (Diff = EUR − 1964.86), chronic liver disease (Diff = EUR − 3595.60), hospitalization (EUR 9419.42 vs. EUR 9055.45), and total mean costs (EUR 11,540.04 vs. 10,221.34) were statistically significant higher in unvaccinated compared to vaccinated patients. The influenza vaccine reduces the costs of hospitalization. There is a need to focus strategies in recommended vaccination groups.

Keywords: influenza vaccination; comorbidity; hospitalization; hospital costs (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/22/14793/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/22/14793/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:22:p:14793-:d:968699

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().